GSK follows its peers into myeloid cell engagers Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 19 November, 2025

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

presented by Where ded­i­ca­tion de­liv­ers ex­cel­lence in bi­o­log­ics

news Alkermes ups bid for Avadel after Lundbeck tried snatching narcolepsy biotech Nabla Bio's AI-made antibodies look more and more ready for prime time GSK picks LTZ Therapeutics in myeloid cell engager pact worth $50M upfront

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Save $200 with Early Bird rates — reserve your spot today.

endpoints pharma Makary skeptical of trial data from China, as FDA pushes 'America First' user fees America is overreliant on China for drug ingredients, a report to Congress finds Arrowhead gets rare lipid disease approval, setting up competition with Ionis Senator questions Lilly CEO on details of Trump deal for weight loss drugs

in case you missed it 1. SixPeaks CEO talks about $170M sale to AstraZeneca and what comes next in obesity 2. Roche’s oral SERD delays early breast cancer recurrence in late-stage trial 3. Vanda says its drug can halve vomiting risk in patients using GLP-1s 4. Exclusive: AI Proteins raises $42M Series A, and will launch miniproteins into hub-and-spoke model 5. Exclusive: Lifordi gets new funding from Sanofi as it preps to test ADC in rheumatoid arthritis 6. News Briefing Merck, Bristol Myers disclose layoffs in New Jersey 7. Top Kennedy Adviser Calley Means to Rejoin Trump Administration 8. Personalized Cancer Vaccines Are Almost Here—But Federal Funding Cuts Could Derail Them Scientific American

.